Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson TALVEY (talquetamab) by Quarter
TALVEY (talquetamab) — Worldwide operational (constant-currency) growth YoY (%) (%)
Johnson & Johnson TALVEY (talquetamab): 42.1% in Q3 2026, down 17.0 pts from a year earlier.
Where the Q3 2026 figure comes from
“|| WW | 171 | 122 | 40.9 | 42.1 | (1.2)”
Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | TALVEY (talquetamab) — Worldwide operational (constant-currency) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 42.1% | -17.0 pts | Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗ |
| Q2 2026 | Jun 28, 2026 | 62.6% | +8.3 pts | Form 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗ |
| Q1 2026 | Mar 29, 2026 | 72.8% | +22.6 pts | Form 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗ |
| Q4 2025 | Dec 28, 2025 | 73.1% | – | Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗ |
| Q3 2025 | Sep 28, 2025 | 59.1% | – | Form 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗ |
| Q2 2025 | Jun 29, 2025 | 54.3% | – | Form 8-K (a2025q2exhibit991.htm, filed 2025-07-16) ↗ |
| Q1 2025 | Mar 30, 2025 | 50.2% | – | Form 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗ |
Breakdown
What makes up TALVEY (talquetamab)
Cite this data
StockData. (2026). Johnson & Johnson TALVEY (talquetamab) (%), quarterly Q1 2025–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-talvey-ops-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.